2022-2027 World Automated Microbiology Market in 92 Countries-Growth Opportunities, 2022 Supplier Shares by Assay, 5-Year Segmentation Forecasts for over 100 Molecular, Identification, Susceptibility, Culture, Urine Screening and Immunodiagnostic Tests-Competitive Strategies and SWOT Analysis, Instrumentation Pipeline, Emerging Technologies, Market Barriers and Risks
This new 92-country survey from LeadingMarketResearch.com provides granular data and analysis not available from any other published source. The survey is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the automated microbiology market during the next five years.
The report is available by section, and can be customized to specific information needs and budget. The report examines key trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for 100 molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
Rationale
The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests. The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratories still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.
The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide.
This comprehensive 92-country survey will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology market, in evaluating emerging opportunities and developing effective business strategies.
Geographic Regions and Countries
Asia-Pacific - 18 countries
Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Turkey, Vietnam
Europe - 38 countries
Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine
Latin America - 22 countries
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela
Middle East - 11 countries
Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates
North America - 3 countries
Canada, Mexico, USA
Specimen Types
Review of major automated molecular diagnostic, multipurpose, specialized, microbial identification, antibiotic susceptibility, blood culture, urine screening, and immunodiagnostic analyzers marketed by Abbott, Halifax, BD, Beckman Coulter/Danaher, Biolog, bioMerieux, Bio-Rad, Cepheid, Curetis, GenMark, Hologic, HTG, Labsystems, Qiagen, Roche, Siemens Healthineers, Sy-Lab, Sysmex, Tecan, Thermo Fisher, Tosoh and other suppliers.
Infectious Diseases Analyzed in the Report
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Technology Review
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
Opportunities and Strategic Recommendations
The report is available by section, and can be customized to specific information needs and budget. The report examines key trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for 100 molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
Rationale
The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests. The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratories still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.
The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide.
This comprehensive 92-country survey will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology market, in evaluating emerging opportunities and developing effective business strategies.
Geographic Regions and Countries
Asia-Pacific - 18 countries
Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Turkey, Vietnam
Europe - 38 countries
Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine
Latin America - 22 countries
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela
Middle East - 11 countries
Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates
North America - 3 countries
Canada, Mexico, USA
Specimen Types
- Urine
- Sterile Fluids: Blood, Serum, CSF
- Throat Swabs, Respiratory Secretions
- Genital Secretions
- Stool
- Abscess/Wound
- Sputum
- Saliva
- Microbial Identification
- Antibiotic Susceptibility
- Urine Screening
- Blood Cultures
Review of major automated molecular diagnostic, multipurpose, specialized, microbial identification, antibiotic susceptibility, blood culture, urine screening, and immunodiagnostic analyzers marketed by Abbott, Halifax, BD, Beckman Coulter/Danaher, Biolog, bioMerieux, Bio-Rad, Cepheid, Curetis, GenMark, Hologic, HTG, Labsystems, Qiagen, Roche, Siemens Healthineers, Sy-Lab, Sysmex, Tecan, Thermo Fisher, Tosoh and other suppliers.
Infectious Diseases Analyzed in the Report
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Technology Review
- Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for the microbiology market.
- Companies developing or marketing microbiology products, by individual test.
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
Opportunities and Strategic Recommendations
- Emerging opportunities for new analyzers, reagents kits, IT and other products with significant market appeal during the next five years.
- Design criteria for decentralized testing products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
I. INTRODUCTION
II. GLOBAL AUTOMATED MICROBIOLOGY MARKET BUSINESS ENVIRONMENT
III. NEW PRODUCT DEVELOPMENT OPPORTUNITIES
IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
V. ALTERNATIVE MARKET PENETRATION STRATEGIES
VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. Introduction
1. Major Factors Affecting Market Penetration for Microbiology Instrumentation
2. Traditional Practices
3. Technological Challenges
4. Automation: Impact on the Microbiology Laboratory and the Patient
B. Major Specimen Types
1. Urine
2. Sterile Fluids: Blood, Serum, and CSF
3. Throat Swabs and Respiratory Secretions
4. Genital Secretions
5. Stool
6. Abscess/Wound
7. Sputum
8. Saliva
C. Test Applications
1. Microbial Identification
2. Antibiotic Susceptibility
3. Urine Screening
a. Photometry
b. Bioluminescence
c. Colorimetric Filtration
d. Enzymatic Detection
e. Optical Detection
4. Blood Cultures
D. Major Automated and Semi-automated Microbiology Systems
1. Multiple Purpose Microbiology Systems
2. Specialized Microbiology Systems
3. Molecular Diagnostic Systems
4. Immunodiagnostic Systems
E. Emerging Diagnostic Technologies
1. Molecular Diagnostics (Amplification Methods, Sequencing, Microarrays/Biochips)
a. DNA Sequencing
b. DNA and RNA Probe Technologies
c. Detection Technologies
d. Biochips: Genosensors, Microarrays, Labs-on-the-Chip
2. Monoclonal Antibodies
3. Immunoassays
4. Differential Light Scattering
5. Information Technology
6. Artificial Intelligence
7. Liposomes
8. Flow Cytometry
9. Chromatography
10. Diagnostic Imaging
11. Gel Microdroplets
12. Other
VIII. COUNTRY MARKET ANALYSES: AUTOMATED MICROBIOLOGY MARKET SHARES AND FORECASTS FOR OVER 100 MOLECULAR, IDENTIFICATION, SUSCEPTIBILITY, CULTURE, URINE SCREENING AND IMMUNODIAGNOSTIC TESTS FOR 92 COUNTRIES:
Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Myanmar, Netherlands, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
IX. COMPETITIVE ASSESSMENTS
Abbott Laboratories
Agilent Technologies
Beckman Coulter/Danaher
bioMerieux
Bio-Rad
DiaSorin
Eiken Chemical
Fujifilm Wako
Fujirebio
Grifols
Instrumentation Laboratory/Werfen
Kyowa Medex
OrthoQuidel
PerkinElmer
Quest Diagnostics
Roche
Siemens Healthineers
Sysmex
Thermo Fisher
Tosoh
II. GLOBAL AUTOMATED MICROBIOLOGY MARKET BUSINESS ENVIRONMENT
III. NEW PRODUCT DEVELOPMENT OPPORTUNITIES
IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
V. ALTERNATIVE MARKET PENETRATION STRATEGIES
VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. Introduction
1. Major Factors Affecting Market Penetration for Microbiology Instrumentation
2. Traditional Practices
3. Technological Challenges
4. Automation: Impact on the Microbiology Laboratory and the Patient
B. Major Specimen Types
1. Urine
2. Sterile Fluids: Blood, Serum, and CSF
3. Throat Swabs and Respiratory Secretions
4. Genital Secretions
5. Stool
6. Abscess/Wound
7. Sputum
8. Saliva
C. Test Applications
1. Microbial Identification
2. Antibiotic Susceptibility
3. Urine Screening
a. Photometry
b. Bioluminescence
c. Colorimetric Filtration
d. Enzymatic Detection
e. Optical Detection
4. Blood Cultures
D. Major Automated and Semi-automated Microbiology Systems
1. Multiple Purpose Microbiology Systems
2. Specialized Microbiology Systems
3. Molecular Diagnostic Systems
4. Immunodiagnostic Systems
E. Emerging Diagnostic Technologies
1. Molecular Diagnostics (Amplification Methods, Sequencing, Microarrays/Biochips)
a. DNA Sequencing
b. DNA and RNA Probe Technologies
c. Detection Technologies
d. Biochips: Genosensors, Microarrays, Labs-on-the-Chip
2. Monoclonal Antibodies
3. Immunoassays
4. Differential Light Scattering
5. Information Technology
6. Artificial Intelligence
7. Liposomes
8. Flow Cytometry
9. Chromatography
10. Diagnostic Imaging
11. Gel Microdroplets
12. Other
VIII. COUNTRY MARKET ANALYSES: AUTOMATED MICROBIOLOGY MARKET SHARES AND FORECASTS FOR OVER 100 MOLECULAR, IDENTIFICATION, SUSCEPTIBILITY, CULTURE, URINE SCREENING AND IMMUNODIAGNOSTIC TESTS FOR 92 COUNTRIES:
Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Myanmar, Netherlands, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
IX. COMPETITIVE ASSESSMENTS
Abbott Laboratories
Agilent Technologies
Beckman Coulter/Danaher
bioMerieux
Bio-Rad
DiaSorin
Eiken Chemical
Fujifilm Wako
Fujirebio
Grifols
Instrumentation Laboratory/Werfen
Kyowa Medex
OrthoQuidel
PerkinElmer
Quest Diagnostics
Roche
Siemens Healthineers
Sysmex
Thermo Fisher
Tosoh
